Q-omics provides the consensus-scored ZACN profile across patient tissues and cancer cell-line models. ZACN expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZACN is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, ZACN RNA expression shows 15,919 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where ZACN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZACN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZACN survival associations across molecular data types. ZACN RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZACN RNA expression–survival associations across cancer types. High ZACN expression shows unfavorable associations in KIRC, ACC, LIHC, KICH and UCS, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZACN RNA expression.
This table summarizes ZACN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZACN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZACN shows lower tumor expression in KICH and higher tumor expression in KIRP, KIRC, LIHC, LUSC and BLCA. The KIRP box plot shows higher ZACN RNA expression in tumor versus normal tissue (log2 FC = +0.355, t-test p < 0.001).
This table shows molecular features associated with ZACN in patient tissues and cancer cell lines. In patient samples, ZACN shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZACN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
